文献速递心脑血管急症消化、代谢与肾脏急症

冠心病患者达标治疗与高强度他汀治疗:一项随机临床试验

Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01
一句话结论冠心病患者以LDL-C 50–70 mg/dL为目标的达标治疗策略,在3年复合终点上不劣于高强度他汀治疗。

该多中心随机非劣效试验纳入4400例冠心病患者,比较以LDL-C 50–70 mg/dL为目标的达标治疗策略与高强度他汀治疗(瑞舒伐他汀20 mg或阿托伐他汀40 mg)。达标治疗组3年平均LDL-C为69.1 mg/dL,高强度他汀组为68.4 mg/dL(P=0.21)。主要终点(3年死亡、心肌梗死、卒中或冠状动脉血运重建复合终点)发生率达标治疗组8.1% vs 高强度他汀组8.7%,绝对差异-0.6个百分点(单侧97.5%CI上限1.1个百分点),非劣效P<0.001。结论提示达标治疗策略不劣于高强度他汀治疗,可能允许根据个体他汀反应差异进行定制化治疗。

要点

  • 冠心病患者以LDL-C 50–70 mg/dL为目标的达标治疗策略,3年主要复合终点发生率8.1% vs 高强度他汀组8.7%,绝对差异-0.6个百分点(单侧97.5%CI上限1.1个百分点),非劣效P<0.001。
  • 达标治疗组3年平均LDL-C为69.1 mg/dL,高强度他汀组为68.4 mg/dL(P=0.21)。
  • 达标治疗组中43%使用中等强度他汀、54%使用高强度他汀;高强度他汀组方案为瑞舒伐他汀20 mg或阿托伐他汀40 mg。
  • 主要终点为3年死亡、心肌梗死、卒中或冠状动脉血运重建复合终点,非劣效界值为3.0个百分点。
  • 该研究为多中心随机非劣效试验,在韩国12个中心进行,纳入4400例冠心病患者。

适用人群与场景

  • 冠心病诊断患者,在韩国12个中心接受治疗。
  • enrollment: 2016年9月9日至2019年11月27日;最终随访:2022年10月26日。

诊断标准与关键阈值

  • 达标治疗策略目标:LDL-C水平在50至70 mg/dL之间。
  • 高强度他汀治疗:瑞舒伐他汀20 mg或阿托伐他汀40 mg。

处置流程与药物剂量

  • 达标治疗组:以LDL-C 50–70 mg/dL为目标,使用中等强度或高强度他汀滴定;该组中43%使用中等强度他汀、54%使用高强度他汀。
  • 高强度他汀组:瑞舒伐他汀20 mg或阿托伐他汀40 mg。

研究设计与关键结果

  • 研究类型:随机、多中心、非劣效试验;样本量4400例;在韩国12个中心进行;纳入冠心病患者;干预为达标治疗策略(LDL-C 50–70 mg/dL)vs 高强度他汀治疗(瑞舒伐他汀20 mg或阿托伐他汀40 mg)。
  • 主要终点:3年死亡、心肌梗死、卒中或冠状动脉血运重建复合终点,非劣效界值3.0个百分点。
  • 主要终点结果:达标治疗组177例(8.1%) vs 高强度他汀组190例(8.7%),绝对差异-0.6个百分点(单侧97.5%CI上限1.1个百分点);非劣效P<0.001。
  • 3年平均LDL-C水平:达标治疗组69.1(17.8)mg/dL vs 高强度他汀组68.4(20.1)mg/dL(P=0.21)。
  • 完成试验:4341例(98.7%);平均(SD)年龄65.1(9.9)岁;女性1228例(27.9%);达标治疗组随访6449人年。

证据类型、等级与局限

  • 证据类型:随机、多中心、非劣效临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现提供了额外证据支持达标治疗策略的适用性,该策略可能允许根据个体对他汀治疗的药物反应差异进行定制化治疗。

指南或共识出处

  • ClinicalTrials.gov Identifier: NCT02579499。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In patients with coronary artery disease, some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in low-density lipoprotein cholesterol (LDL-C). An alternative approach is to begin with moderate-intensity statins and titrate to a specific LDL-C goal. These alternatives have not been compared head-to-head in a clinical trial involving patients with known coronary artery disease.

OBJECTIVE: To assess whether a treat-to-target strategy is noninferior to a strategy of high-intensity statins for long-term clinical outcomes in patients with coronary artery disease.

DESIGN, SETTING, AND PARTICIPANTS: A randomized, multicenter, noninferiority trial in patients with a coronary disease diagnosis treated at 12 centers in South Korea (enrollment: September 9, 2016, through November 27, 2019; final follow-up: October 26, 2022).

INTERVENTIONS: Patients were randomly assigned to receive either the LDL-C target strategy, with an LDL-C level between 50 and 70 mg/dL as the target, or high-intensity statin treatment, which consisted of rosuvastatin, 20 mg, or atorvastatin, 40 mg.

MAIN OUTCOMES AND MEASURES: Primary end point was a 3-year composite of death, myocardial infarction, stroke, or coronary revascularization with a noninferiority margin of 3.0 percentage points.

RESULTS: Among 4400 patients, 4341 patients (98.7%) completed the trial (mean [SD] age, 65.1 [9.9] years; 1228 females [27.9%]). In the treat-to-target group (n = 2200), which had 6449 person-years of follow-up, moderate-intensity and high-intensity dosing were used in 43% and 54%, respectively. The mean (SD) LDL-C level for 3 years was 69.1 (17.8) mg/dL in the treat-to-target group and 68.4 (20.1) mg/dL in the high-intensity statin group (n = 2200) (P = .21, compared with the treat-to-target group). The primary end point occurred in 177 patients (8.1%) in the treat-to-target group and 190 patients (8.7%) in the high-intensity statin group (absolute difference, -0.6 percentage points [upper boundary of the 1-sided 97.5% CI, 1.1 percentage points]; P < .001 for noninferiority).

CONCLUSIONS AND RELEVANCE: Among patients with coronary artery disease, a treat-to-target LDL-C strategy of 50 to 70 mg/dL as the goal was noninferior to a high-intensity statin therapy for the 3-year composite of death, myocardial infarction, stroke, or coronary revascularization. These findings provide additional evidence supporting the suitability of a treat-to-target strategy that may allow a tailored approach with consideration for individual variability in drug response to statin therapy.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02579499.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Hong SJ, Lee YJ, Lee SJ, et al. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2023. PMID: 36877807. doi:10.1001/jama.2023.2487

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。